间充质干细胞治疗新型冠状病毒肺炎的研究

当前国内新型冠状病毒肆虐，严重危害人们健康。新型冠状病毒感染性强，感染后的重型患者病死率高，尚无有效治疗方法。间充质干细胞具有强大的抗炎和免疫调节功能，通过抑制肺部浸润的免疫细胞减轻急慢性肺损伤，并降低炎性因子分泌水平，降低细胞因子风暴和急性呼吸窘迫综合征发生的风险，有望降低患者的死亡率；同时间充质干细胞具有降低肺部纤维化水平、增强组织损伤修复的能力，是治疗难治性肺损伤相关疾病的一种具有良好临床前景的选择。结合临床前及临床研究的有关进展，对间充质干细胞治疗新型冠状病毒肺炎进行有效性评价。

Therapy of novel coronavirus pneumonia with mesenchymal stem cells

At present, China is the focus of global attention due to an outbreak of a febrile respiratory illness due to a new novel coronavirus SARS-COV-2, which seriously endangers people''s health. The new type of coronavirus is highly infectious, and the mortality of severe patients with the novel coronavirus pneumonia is high. However, there is no effective treatment method. It is urgent to find a safe and effective treatment. Studies have found that mesenchymal stem cells have powerful anti-inflammatory and immunoregulatory functions. They can reduce acute and chronic lung injury by suppressing lung infiltrating immune cells, and reduce the secretion of inflammatory factors. At the same time, MSCs can reduce the lung fibrosis level and could markedly improve the degree of lung ability. It is a promising treatment option of refractory lung injury-related diseases with mesenchymal stem cells. This article reviews preclinical and clinical research and evaluate the effectiveness of mesenchymal stem cells in the treatment of novel coronavirus pneumonia.